Nava to present preclinical data in two oral presentations at ASGCT 2026. Learn more
RNA therapeutics.
Beyond limits.
RNA delivery,
precisely where it matters.
Nava is building a new class of genetic medicines harnessing novel lipid nanoparticles (LNPs) able to deliver RNA therapeutics to organs and cellular targets with unparalleled precision and efficiency. This approach powers breakthroughs across the full spectrum of RNA therapeutics.
By delivering therapies exactly where needed, we are opening new possibilities for patients with serious diseases that remain beyond the reach of current treatments.
LNPs by design,
not by default.
We are unlocking the full potential of genetic medicine by addressing some of its most pressing challenges: delivering RNA safely and precisely to the right cells at clinically relevant doses.
Through rational design and exploration of novel chemical space, Nava has built a modular platform of LNPs with unique and selective tropism for a broad range of tissues. Our LNPs enable safe and precise RNA delivery to organs and cellular targets of choice, with an initial therapeutic focus on areas of high unmet medical need.